Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Chordia Therapeutics Inc. ( (JP:190A) ) has issued an announcement.
Chordia Therapeutics Inc., a Japan-based oncology-focused biopharmaceutical developer, is advancing its pipeline of targeted cancer therapies led by rogocekib (CLK inhibitor CTX-712) in a Phase 1/2 U.S. trial. The company is also researching additional programs such as CTX-177, CTX-439, and GCN2 inhibitors to address a range of malignancies through precision approaches.
Chordia has decided to begin expansion cohorts in its ongoing Phase 1/2 study of rogocekib in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes in the United States, after an independent committee confirmed a dose level meeting predefined safety and efficacy criteria. The two-stage expansion, designed under U.S. FDA Project Optimus principles, will refine dosing, regimen, and tumor type to establish a recommended Phase 2 dose, with Phase 2 initiation targeted around mid‑2027 and dose-escalation data slated for presentation at an international conference in mid‑2026.
The most recent analyst rating on (JP:190A) stock is a Hold with a Yen111.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a Japan-based biopharmaceutical company focused on discovering and developing targeted cancer therapies. Its lead asset, rogocekib (CLK inhibitor CTX-712), is in a Phase 1/2 trial in the United States, and the company is also advancing a pipeline that includes a MALT1 inhibitor, a CDK12 inhibitor, and GCN2 inhibitors for various tumor types.
The company’s strategy centers on exploiting molecular vulnerabilities in cancer to deliver precision treatments for patients with hematologic malignancies and solid tumors. By progressing multiple early-stage assets in parallel, Chordia aims to build a diversified oncology portfolio and strengthen its position in the global cancer drug development landscape.
Average Trading Volume: 975,054
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.97B
For an in-depth examination of 190A stock, go to TipRanks’ Overview page.